Lupus Nephritis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Lupus Nephritis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
as Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Lupus Nephritis pipeline constitutes 20+ key companies continuously working towards developing 20+ Lupus Nephritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Lupus Nephritis Overview

Lupus Nephritis (LN), is one of the most severe organ manifestations of systemic lupus erythematosus (SLE) which is an autoimmune disorder leading to the loss of immune tolerance of endogenous nuclear material resulting in systemic autoimmunity that causes damage to various tissues and organs.

 

Lupus Nephritis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lupus Nephritis Market.

 

The Lupus Nephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Lupus Nephritis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Lupus Nephritis treatment therapies with a considerable amount of success over the years. Lupus Nephritis Key players such as – Neutrolis Therapeutics, Eledon Pharmaceuticals, Equillium, BeiGene, Janssen Research & Development, Boehringer Ingelheim, Novartis, Roche, and others, are developing therapies for the Lupus Nephritis treatment 
  • Lupus Nephritis Emerging therapies such as – NTR-441, AT-1501, Itolizumab, Zanubrutinib, Guselkumab, BI-655064, Secukinumab, Obinutuzumab, and others are expected to have a significant impact on the Lupus Nephritis market in the coming years.   
  • Roche initiated a phase III randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Obinutuzumab in patients with ISN/RPS 2003 Class III Or IV lupus nephritis.
  • In December 2020, the U.S. Food and Drug Administration (FDA) approved voclosporin (brand name: Lupkynis) for the treatment of adults with active lupus nephritis.

 

Route of Administration

Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Small molecule
  • Product Type

 

Lupus Nephritis Pipeline Therapeutics Assessment

  • Lupus Nephritis Assessment by Product Type
  • Lupus Nephritis By Stage and Product Type
  • Lupus Nephritis Assessment by Route of Administration
  • Lupus Nephritis By Stage and Route of Administration
  • Lupus Nephritis Assessment by Molecule Type
  • Lupus Nephritis by Stage and Molecule Type

 

DelveInsight’s Lupus Nephritis Report covers around 20+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Lupus Nephritis Therapeutics Market include:

Key companies developing  therapies for Lupus Nephritis are – Aurinia Pharmaceuticals, GSK (GlaxoSmithKline), AstraZeneca, Pfizer, Roche, Bristol Myers Squibb, Merck & Co., Sanofi, Eli Lilly and Company, Novartis, Biogen, AbbVie, Johnson & Johnson, Boehringer Ingelheim, Celgene (now part of Bristol Myers Squibb), Alexion Pharmaceuticals (now part of AstraZeneca), Mylan (now part of Viatris), Teva Pharmaceutical Industries, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, and others

 

Emerging Lupus Nephritis Drugs Under Different Phases of Clinical Development Include:

  • NTR-441: Neutrolis Therapeutics
  • AT-1501: Eledon Pharmaceuticals
  • Itolizumab: Equillium
  • Zanubrutinib: BeiGene
  • Guselkumab: Janssen Research & Development
  • BI-655064: Boehringer Ingelheim
  • Secukinumab: Novartis
  • Obinutuzumab: Roche

 

Get a Free Sample PDF Report to know more about Lupus Nephritis Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight

 

Lupus Nephritis Pipeline Analysis:

The Lupus Nephritis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Lupus Nephritis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis Treatment.
  • Lupus Nephritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Lupus Nephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lupus Nephritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Lupus Nephritis product details are provided in the report. Download the Lupus Nephritis pipeline report to learn more about the emerging Lupus Nephritis therapies

 

Scope of Lupus Nephritis Pipeline Drug Insight    

  • Coverage: Global
  • Key Lupus Nephritis Companies: Neutrolis Therapeutics, Eledon Pharmaceuticals, Equillium, BeiGene, Janssen Research & Development, Boehringer Ingelheim, Novartis, Roche, and others
  • Key Lupus Nephritis Therapies: NTR-441, AT-1501, Itolizumab, Zanubrutinib, Guselkumab, BI-655064, Secukinumab, Obinutuzumab, and others
  • Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
  • Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers 

 

Request for Sample PDF Report for Lupus Nephritis Pipeline Assessment and clinical trials

 

Table of Contents

1

Lupus Nephritis Report Introduction

2

Lupus Nephritis Executive Summary

3

Lupus Nephritis Overview

4

Lupus Nephritis- Analytical Perspective In-depth Commercial Assessment

5

Lupus Nephritis Pipeline Therapeutics

6

Lupus Nephritis Late Stage Products (Phase II/III)

7

Lupus Nephritis Mid Stage Products (Phase II)

8

Lupus Nephritis Early Stage Products (Phase I)

9

Lupus Nephritis Preclinical Stage Products

10

Lupus Nephritis Therapeutics Assessment

11

Lupus Nephritis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Lupus Nephritis Key Companies

14

Lupus Nephritis Key Products

15

Lupus Nephritis Unmet Needs

16 

Lupus Nephritis Market Drivers and Barriers

17

Lupus Nephritis Future Perspectives and Conclusion

18

Lupus Nephritis Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Lupus Nephritis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com


Posted

in

by

Tags: